Linked Life Data

8114303

Source:http://linkedlifedata.com/resource/pubmed/id/8114303

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1994-3-25
pubmed:abstractText
Primary biliary cirrhosis (PBC) is thought to be an autoimmune disorder with additional liver injury being mediated by the subsequent cholestasis and accumulation of toxic bile acids. The combination therapy with ursodeoxycholic acid and colchicine is considered most effective and safe, among various therapeutic agents, such as corticosteroids, penicillamine, azathioprine and cyclosporine A for PBC patients. Several clinical trials using this combination therapy have shown significant improvement in symptoms and biochemical parameters, and a possibility of prolonging survival period. The survival of asymptomatic PBC patients may be more than 10 years. However, the clinical course may rapidly progress and show a poor prognosis, when jaundice occurs (bilirubin levels > 2 mg/dl). Liver transplantation remains the only choice of treatment at the end stage of the disease.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0047-1852
pubmed:author
pubmed:issnType
Print
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
256-61
pubmed:dateRevised
2011-7-27
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
[Primary biliary cirrhosis: therapy and prognosis].
pubmed:affiliation
First Department of Internal Medicine, Yamaguchi University Medical School.
pubmed:publicationType
Journal Article, English Abstract, Review